DOAJ Open Access 2019

Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target

Maria Rosaria Sapienza Francesco Abate Federica Melle Stefania Orecchioni Fabio Fuligni +26 lainnya

Abstrak

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy for which there is still no effective therapy. In order to identify genetic alterations useful for a new treatment design, we used whole-exome sequencing to analyze 14 BPDCN patients and the patient-derived CAL-1 cell line. The functional enrichment analysis of mutational data reported the epigenetic regulatory program to be the most significantly undermined (P

Topik & Kata Kunci

Diseases of the blood and blood-forming organs

Penulis (31)

Maria Rosaria Sapienza

Francesco Abate

Federica Melle

Stefania Orecchioni

Fabio Fuligni

Maryam Etebari

Valentina Tabanelli

Maria Antonella Laginestra

Alessandro Pileri

Giovanna Motta

Maura Rossi

Claudio Agostinelli

Elena Sabattini

Nicola Pimpinelli

Mauro Truni

Brunangelo Falini

Lorenzo Cerroni

Giovanna Talarico

Rossana Piccioni

Stefano Amente

Valentina Indio

Giuseppe Tarantino

Francesco Brundu

Marco Paulli

Emilio Berti

Fabio Facchetti

Gaetano Ivan Dellino

Francesco Bertolini

Claudio Tripodo

Raul Rabadan

Stefano A. Pileri

Format Sitasi

APA MLA BibTeX

Sapienza, M.R., Abate, F., Melle, F., Orecchioni, S., Fuligni, F., Etebari, M. et al. (2019). Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. https://doi.org/10.3324/haematol.2018.202093

Akses Cepat

PDF tidak tersedia langsung

Cek di sumber asli →

Lihat di Sumber doi.org/10.3324/haematol.2018.202093

Informasi Jurnal

Tahun Terbit: 2019
Sumber Database: DOAJ
DOI: 10.3324/haematol.2018.202093
Akses: Open Access ✓